A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS).
OBJECTIVE
The aim of this study was to determine the efficacy and safety of docetaxel plus epirubicin combination as first-line chemotherapy in patients with locally advanced and/or metastatic adult STS.


METHODS
Eighteen patients were treated with epirubicin 30 mg/m(2) on days 1 to 3 and docetaxel 100 mg/m(2) on day 1 every 3 weeks.


RESULTS
Fifteen out of 18 patients (83.4%) were assessable for response. No complete response was recorded. Three (20%) patients achieved PR, 3 had SD and 9 PD. The overall median survival was 14 months (range, 3-48 months) and the median time to disease progression was 4 months (range, 2-45 months). Grade >/= 3 neutropenia occurred in 88% and neutropenic fever in 27.8% of patients. Other toxicities were mild. No treatment related deaths occurred.


CONCLUSIONS
Docetaxel plus epirubicin combination achieved low response rate with severe myelotoxicity in patients with advanced STS.
Kalofonos
Haralabos P
HP
Division of Oncology Department of Medicine University Hospital Patras Medical School Rion 26504 Greece.
Kourousis
Charalabos
C
Karamouzis
Michalis V
MV
Iconomou
Gregoris
G
Tsiata
Ekaterini
E
Tzorzidis
Fotis
F
Megas
Panagiotis
P
Lambiris
Elias
E
Georgoulias
Vasilios
V